Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2021 Oct 27

PMID 34703271

Citations 4

Authors

Xiaoxiao Zhao

Li Song

Ying Wang

Jiannan Li

Jinying Zhou

Runzhen Chen

Chen Liu

Peng Zhou

Zhaoxue Sheng

Yi Chen

Hanjun Zhao

Hongbing Yan

Affiliations

Soon will be listed here.

Abstract

Background And Aim: The aim of prospective study was to determine the prognostic value of combined measures of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and pentraxin 3 (PTX3) according to the culprit-plaque morphology (plaque rupture versus plaque erosion) in relation to the in patients with acute ST-elevated myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention.

Methods: A total of 434 patients with STEMI aged ≥18 years who underwent pre-intervention OCT imaging of culprit lesions between March 2017 and March 2019 were enrolled. Finally, 235 patients who meet the inclusion criteria were enrolled and the cohort was divided into 3 groups according to PCSK9 and PTX3 levels: group A: PCSK9 < median and Pentraxin 3 (N = 72/30.6%); group B: PCSK9 ≥ median or Pentraxin 3≥ median (N = 91/38.7%); group C: PCSK9 ≥ median and Pentraxin 3≥ median (N = 72/30.6%). MACEs were defined as a composite of all-cause death, myocardial infarction (MI) recurrence, and ischemic stroke, revascularization and heart failure.

Outcomes: During a median follow-up of 2.01 years, 50 patients has occurred MACE. Two-year MACE was higher in group C (23/31.9%) than in group B (16/17.6%) and group A (11/15.3%) (p = 0.028). There was a correlation between PCSK9 and PTX3 (r = 0.302, p < 0.003). In multivariable analysis adjusted for age, gender, risk factors, and serum indexes, being in group C remained independently associated with an increased risk of MACE (hazard ratio [HR]: 2.90; p = 0.010), and group B tended to have higher MACE (HR: 1.76; p = 0.172) compared with group A. Among patients with plaque erosion by OCT, group C was independently associated with an increased risk of MACE (HR: 9.04; p = 0.048) after fully adjustment. However, the significant association was absence among patients with plaque rupture.

Conclusion And Relevance: This study demonstrated the usefulness of combined measures of PCSK9 and PTX3 to enhance risk stratification in patients with STEMI especially among patients with plaque erosion. Patients with elevation of both PCSK9 and PTX3 had a markedly increased risk of MACE.

Citing Articles

Elevated Circulating Adipocyte-Fatty Acid Binding Protein Levels Predict Incident Ischemic Cardiovascular Events in a Longitudinal and Prospective AMI Aging Study.

Zhao X, Zhao H, Chen R, Zhou J, Li N, Li J J Inflamm Res. 2025; 18:1589-1608.

PMID: 39925937 PMC: 11806690. DOI: 10.2147/JIR.S494049.

Coronary Plaque Erosion: Epidemiology, Diagnosis, and Treatment.

Theofilis P, Vlachakis P, Papanikolaou A, Karakasis P, Oikonomou E, Tsioufis K Int J Mol Sci. 2024; 25(11).

PMID: 38891972 PMC: 11171599. DOI: 10.3390/ijms25115786.

Longitudinal change of serum exosomal miR-186-5p estimates major adverse cardiac events in acute myocardial infarction patients receiving percutaneous coronary intervention.

Ren L, Liu W, Chen S, Zeng H Front Cardiovasc Med. 2024; 11:1341918.

PMID: 38694565 PMC: 11061486. DOI: 10.3389/fcvm.2024.1341918.

The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarction.

Sawaguchi J, Saeki Y, Oda M, Takamura T, Fujibayashi K, Wakasa M Atheroscler Plus. 2023; 50:50-56.

PMID: 36643795 PMC: 9833232. DOI: 10.1016/j.athplu.2022.09.002.

Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study.

Chen R, Zhao H, Zhou J, Wang Y, Li J, Zhao X Biomolecules. 2022; 12(10).

PMID: 36291690 PMC: 9599865. DOI: 10.3390/biom12101482.

References

Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, Cuccovillo I . Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med. 2010; 36(4):621-9. DOI: 10.1007/s00134-010-1752-5. View

Sabatine M, Leiter L, Wiviott S, Giugliano R, Deedwania P, De Ferrari G . Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5(12):941-950. DOI: 10.1016/S2213-8587(17)30313-3. View

Nebuloni M, Pasqualini F, Zerbi P, Lauri E, Mantovani A, Vago L . PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis. Cardiovasc Pathol. 2010; 20(1):e27-35. DOI: 10.1016/j.carpath.2010.02.005. View

Sabatine M, Giugliano R, Keech A, Honarpour N, Wiviott S, Murphy S . Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376(18):1713-1722. DOI: 10.1056/NEJMoa1615664. View

Kaptoge S, Di Angelantonio E, Lowe G, Pepys M, Thompson S, Collins R . C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2009; 375(9709):132-40. PMC: 3162187. DOI: 10.1016/S0140-6736(09)61717-7. View

Du Clos T . Function of C-reactive protein. Ann Med. 2000; 32(4):274-8. DOI: 10.3109/07853890009011772. View

Vecchie A, Bonaventura A, Meessen J, Novelli D, Minetti S, Elia E . PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study. J Intern Med. 2020; 289(2):179-192. DOI: 10.1111/joim.13150. View

Kastelein J, Akdim F, Stroes E, Zwinderman A, Bots M, Stalenhoef A . Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358(14):1431-43. DOI: 10.1056/NEJMoa0800742. View

Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B . Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001; 29(7):1404-7. DOI: 10.1097/00003246-200107000-00017. View

10.

Yahagi K, Kolodgie F, Lutter C, Mori H, Romero M, Finn A . Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2016; 37(2):191-204. PMC: 5269516. DOI: 10.1161/ATVBAHA.116.306256. View

11.

Ding Z, Liu S, Wang X, Deng X, Fan Y, Sun C . Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal. 2014; 22(9):760-71. PMC: 4361218. DOI: 10.1089/ars.2014.6054. View

12.

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

13.

Pearson T, Mensah G, Hong Y, Smith Jr S . CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: overview. Circulation. 2004; 110(25):e543-4. DOI: 10.1161/01.CIR.0000148979.11121.6B. View

14.

Sabatine M, Giugliano R, Wiviott S, Raal F, Blom D, Robinson J . Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1500-9. DOI: 10.1056/NEJMoa1500858. View

15.

Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X . Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol. 2014; 13:146. PMC: 4209231. DOI: 10.1186/s12933-014-0146-3. View

16.

Liu S, Qu X, Liu F, Wang C . Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection. Mediators Inflamm. 2014; 2014:421429. PMC: 4235333. DOI: 10.1155/2014/421429. View

17.

Momtazi-Borojeni A, Sabouri-Rad S, Gotto A, Pirro M, Banach M, Awan Z . PCSK9 and inflammation: a review of experimental and clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2019; 5(4):237-245. DOI: 10.1093/ehjcvp/pvz022. View

18.

Jenny N, Arnold A, Kuller L, Tracy R, Psaty B . Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009; 29(4):594-9. PMC: 2661204. DOI: 10.1161/ATVBAHA.108.178947. View

19.

Brandes R, Kreuzer J . Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res. 2004; 65(1):16-27. DOI: 10.1016/j.cardiores.2004.08.007. View

20.

Tearney G, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra H . Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012; 59(12):1058-72. DOI: 10.1016/j.jacc.2011.09.079. View